| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MEDP | Common Stock | Sale | -$20.1M | -50K | -0.96% | $401.88 | 5.18M | Feb 27, 2024 | By Medpace Investors, LLC | F1, F2, F3 |
| transaction | MEDP | Common Stock | Sale | -$20.2M | -50K | -0.96% | $404.13 | 5.13M | Feb 28, 2024 | By Medpace Investors, LLC | F1, F3, F4 |
| holding | MEDP | Common Stock | 807K | Feb 27, 2024 | Direct |
| Id | Content |
|---|---|
| F1 | The transactions reported on this Form 4 were effected pursuant to a limit order placed by Medpace Investors, LLC ("MPI") during an open window period. |
| F2 | The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $398.84 to $404.17. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. |
| F3 | The Reporting Person is the sole manager and controlling unit holder of MPI and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein. |
| F4 | The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $400.105 to $407.27. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request. |